CheckMate 9DX — Adjuvant nivolumab versus placebo in hepatocellular carcinoma at high risk of recurrence after resection or ablation

Phase 3 · Hepatocellular Carcinoma, Liver Cancer

Population

Hepatocellular carcinoma at high risk of recurrence after curative-intent surgical resection or ablation.

Primary Endpoint

Recurrence-free survival

Rationale

The majority of patients relapse within five years of curative treatment for HCC, and no adjuvant therapy has been proven to reduce that risk. CheckMate 9DX tests whether adjuvant nivolumab lowers recurrence in high-risk patients.

What It Could Change

Would answer whether adjuvant immunotherapy has a role after potentially curative treatment for liver cancer.